President Joe Biden listens to Pfizer CEO Albert Bourla speak at Pfizer’s Kalamazoo manufacturing site on February 19, 2021, in Portage, Michigan.
Brendan Smialowski | AFP | Getty Images
Pfizer plans to leverage mRNA technology to make new vaccines against other viruses following the success of its Covid-19 trait, which was developed in conjunction with German partner BioNTech, the Wall Street Journal reported Tuesday.
The drug maker said it was willing to search for mRNA by itself after its experience last year working on the COVID-19 vaccine, the WSJ reported, citing an interview with Albert Bourla, CEO of Pfizer.
However, he did not reveal any details about the viruses he was targeting.
Pfizer and BioNTech did not immediately respond to Reuters’ requests for comment.
Pfizer / BioNTech and Moderna Covid-19 vaccines, authorized for emergency use in the United States, use mRNA technology.
The success of the technology makes drug developers consider its use in other areas of medicine beyond vaccines, and will attract billions of dollars in investments.